Perrigo Company Company Profile (NYSE:PRGO)

Perrigo Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."

Perrigo Company declared a quarterly dividend on Tuesday, August 8th. Stockholders of record on Friday, August 25th will be given a dividend of $0.16 per share on Tuesday, September 12th. This represents a $0.64 annualized dividend and a dividend yield of 0.75%. The ex-dividend date is Wednesday, August 23rd. View Perrigo Company's Dividend History.

Perrigo Company (NYSE:PRGO) announced its quarterly earnings results on Thursday, August, 10th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.94 by $0.28. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.18 billion. Perrigo Company had a negative net margin of 51.04% and a positive return on equity of 11.55%. The company's revenue for the quarter was down 7.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.93 EPS. View Perrigo Company's Earnings History.

Perrigo Company is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Perrigo Company.

Perrigo Company issued an update on its FY17 earnings guidance on Thursday, August, 10th. The company provided EPS guidance of $4.45-4.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.28.

16 equities research analysts have issued 1-year target prices for Perrigo Company's shares. Their forecasts range from $64.00 to $125.00. On average, they expect Perrigo Company's stock price to reach $87.77 in the next year. View Analyst Ratings for Perrigo Company.

Here are some recent quotes from research analysts about Perrigo Company stock:

• 1. Canaccord Genuity analysts commented, "Date and time of first dissemination: May 22, 2017, 23:13 ET Date and time of production: May 22, 2017, 22:26 ET Target Price / Valuation Methodology: Perrigo Company – PRGO Discounted cash flow analysis supports an $86 valuation for PRGO shares Our discounted cash flow (DCF) analysis leads us to a price target of $86/share for PRGO. Our DCF considers our estimates through 2021, low-single-digit growth through 2033 and zero terminal growth thereafter. In addition, we expect Perrigo’s margin structure to remain somewhat consistent with our 2021 estimates." (5/22/2017)
• 2. Deutsche Bank AG analysts commented, "We updated our model to reflect PRGO's divestiture of the Tysabri royalty stream to Royalty Pharma, which the company expects to complete this month, and preliminary assumptions for de-leveraging with the proceeds. The net effect of these changes was EPS dilution of ~15-20% over 2017-21 and a reduction in our DCF-derived PT to $87 (from $93), as our prior model reflected more value for the Tysabri royalty stream (~$3bn) relative to the upfront payment of $2.2bn. We have not factored in the potential sales-based milestone payments of $650mn, which could add ~$4/share to the theoretical DCF value if they hit. We continue to view PRGO as a unique asset with good value creation potential over the longer term, and are maintaining our Buy rating. Solid execution in the coming quarters will be critical for the stock, in our view." (3/14/2017)
• 3. Jefferies Group LLC analysts commented, "Unaudited Q4 results were ahead of forecast. But the real story is FY17 guidance and it disappointed even after sharp cuts to Street models just 4 weeks ago. For the first time we can recall both rev & EPS will decline ' not a good story line for an OTC-focused company. Tysabri's sale helps de-lever PRGO but at the same time shrinks the EPS base by ~$2.20. Mgt continues to make moves to enhance shareholder value ' but it may take quite some time to do so." (2/28/2017)
• 4. Royal Bank Of Canada analysts commented, "While we expected a challenging 2017 guide, it was worse than we anticipated and came with an unexpected CFO departure. The strategic review around whether to sell Rx/generics will linger, limiting visibility but the conundrum is that we do not see upside in either scenario. We remain on the sidelines with target down to $68. Several additional thoughts after speaking with management this evening." (2/28/2017)

Some companies that are related to Perrigo Company include Incyte Corporation (INCY), Edwards Lifesciences Corporation (EW), C.R. Bard (BCR), Cerner Corporation (CERN), Zimmer Biomet Holdings (ZBH), Cardinal Health (CAH), Quintiles Transitional Holdings (Q), Lonza Group Ag (LZAGY), AmerisourceBergen Corporation (Holding Co) (ABC), Teva Pharmaceutical Industries Limited (TEVA), Mylan N.V. (MYL), BioMarin Pharmaceutical (BMRN), Laboratory Corporation of America Holdings (LH), Centene Corporation (CNC), Smith & Nephew SNATS (SNN), Eisai Co., Ltd (ESALY), Align Technology (ALGN) and Grifols, S.A. (GRFS).

Perrigo Company's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.37%), BlackRock Inc. (8.27%), Franklin Resources Inc. (5.66%), State Street Corp (4.72%), Capital Research Global Investors (2.14%) and Aberdeen Asset Management PLC UK (2.11%). Company insiders that own Perrigo Company stock include Gary K Kunkle Jr, Geoffrey M Parker, Herman Morris Jr, Jeffrey Needham, Joseph C Papa, Judy L Brown, Michael J Jandernoa, Sharon Kochan and Thomas Farrington. View Institutional Ownership Trends for Perrigo Company.

Perrigo Company's stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Clal Insurance Enterprises Holdings Ltd, State of New Jersey Common Pension Fund D, North Tide Capital LLC, BlackRock Inc., Bank of New York Mellon Corp, Wells Fargo & Company MN and Cullen Frost Bankers Inc.. Company insiders that have sold Perrigo Company stock in the last year include Jeffrey Needham, Judy L Brown, Sharon Kochan and Thomas Farrington. View Insider Buying and Selling for Perrigo Company.

Perrigo Company's stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Migdal Insurance & Financial Holdings Ltd., Renaissance Technologies LLC, Gotham Asset Management LLC, Neuberger Berman Group LLC, Goldman Sachs Group Inc., Vanguard Group Inc. and Ameriprise Financial Inc.. View Insider Buying and Selling for Perrigo Company.

Shares of Perrigo Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Perrigo Company stock can currently be purchased for approximately $84.93.